EPB41L5 and breast carcinoma: We first found that EPB41L5 is highly expressed in breast cancer cells, including MDA-MB-231, which exhibit mesenchymal properties (that is, are vimentin-positive29) and express ARF6 and AMAP1 at high levels20, 21 (Figure 1a).